login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
PTC THERAPEUTICS INC (PTCT) Stock News
NASDAQ:PTCT -
US69366J2006
-
Common Stock
58.01
USD
+2.46 (+4.43%)
Last: 9/4/2025, 4:41:34 PM
58.01
USD
0 (0%)
After Hours:
9/4/2025, 4:41:34 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PTCT Latest News, Press Relases and Analysis
All
Press Releases
14 days ago - By: Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock
7 days ago - By: Yahoo Finance
- Mentions:
NVS
PTC
PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich’s Ataxia
14 days ago - By: Benzinga
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump
14 days ago - By: PTC Therapeutics, Inc.
PTC Therapeutics to Participate at Upcoming Investor Conferences
15 days ago - By: Yahoo Finance
- Mentions:
RY
RY.CA
PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital
16 days ago - By: Benzinga
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
a month ago - By: The Motley Fool
- Mentions:
NVS
PTCT Earnings Beat but Sales Drop 4%
a month ago - By: Zacks Investment Research
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say
a month ago - By: Zacks Investment Research
- Mentions:
XOMA
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates
a month ago - By: PTC Therapeutics, Inc.
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
a month ago - By: PTC Therapeutics, Inc.
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
2 months ago - By: PTC Therapeutics, Inc.
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results
2 months ago - By: PTC Therapeutics, Inc.
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
2 months ago - By: PTC Therapeutics, Inc.
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
3 months ago - By: Yahoo Finance
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches
3 months ago - By: ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
3 months ago - By: PTC Therapeutics, Inc.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
3 months ago - By: The Schall Law Firm
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Please enable JavaScript to continue using this application.